In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not diabetic, to lose significant amounts of weight.

Those on the highest 36 mg dose of the medicine on average lost 12.4 per cent of their body weight at 72 weeks

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, according to topline results from its first of two late-stage clinical trials.